Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Dotinurad,Allopurinol
Therapeutic Area : Rheumatology
Study Phase : Phase I/ Phase II
Sponsor : Novo Holdings
Deal Size : $205.0 million
Deal Type : Series A Financing
Novo-Backed Crystalys Debuts With $205M to Tackle Gout
Details : The financing round will support the advancement of Phase 3 evaluating, FYU-981 (dotinurad), a next-generation, once daily oral, URAT1 inhibitor for the treatment of gout.
Product Name : FYU-981
Product Type : Miscellaneous
Upfront Cash : Undisclosed
September 30, 2025
Lead Product(s) : Dotinurad,Allopurinol
Therapeutic Area : Rheumatology
Highest Development Status : Phase I/ Phase II
Sponsor : Novo Holdings
Deal Size : $205.0 million
Deal Type : Series A Financing